Company / Current Liabilities
Jazz Pharmaceuticals Current Liabilities History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Liabilities
$2.2B
FY2025
5-year range
$809.3M / $2.2B
FY2021-FY2025
Trend
+115.9%
vs FY2024
Sector context
#16 of 213
Health Care
What the data says
Among 213 Health Care companies, Jazz Pharmaceuticals is in the bottom 8% for current liabilities. Increased from $1.5B to $2.2B over the past 2 years.
Based on SEC 10-K filings.
$2.2B in FY2025 with a 5-year CAGR of +28.0%. Top quartile in the Health Care sector.
Increased from $1.5B to $2.2B over the past 2 years.
Health Care sector context is included.
Current Liabilities over time
Growth rates
- 3-Year CAGR
- +33.9%
- 5-Year CAGR
- +28.0%
- 10-Year CAGR
- -
Sector benchmark
Bottom 8% in Health CareTop 92% of 213This company $2.2B Sector average $1.6B
▼
+41.2% above sector average
Key checks
Key Insights
- 5-year CAGR of +28.0%, indicating consistent growth.
- In FY2025, current liabilities increased 115.9% year-over-year.
- Ranks #16 out of 213 companies in the Health Care sector.
- Lowest current liabilities in the period was in FY2016.
Company context
Key Data Points
- Altman Z-Score 0.66 (distress zone, below 1.8 threshold)
- Negative profit margin: -8.9%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current LiabilitiesValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $2.2B | +115.9% |
| FY2024 | $1.0B | -32.4% |
| FY2023 | $1.5B | +64.7% |
| FY2022 | $933.2M | +15.3% |
| FY2021 | $809.3M | +23.8% |
| FY2020 | $653.7M | +79.4% |
| FY2019 | $364.5M | +5.5% |
| FY2018 | $345.5M | +17.5% |
| FY2017 | $293.9M | +14.2% |
| FY2016 | $257.4M | +13.6% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026